In vitro maturation of B cells in chronic lymphocytic leukemia. I. Synergistic action of phorbol ester and interleukin 2 in the induction of Tac antigen expression and interleukin 2 responsiveness in leukemic B cells.
Open Access
- 1 October 1985
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 135 (4) , 2876-2881
- https://doi.org/10.4049/jimmunol.135.4.2876
Abstract
Recent evidence indicates that interleukin 2 (IL 2), formerly thought to serve as growth factor exclusively for activated T cells, is directly involved in human B cell differentiation. We have investigated the role of IL 2 and IL 2 receptors (as defined by monoclonal anti-Tac antibody) in the phorbol ester-induced in vitro maturation of leukemic B cells from patients with chronic lymphocytic leukemia (CLL). Peripheral blood lymphocytes from B cells from CLL patients with high (greater than 10(5)/microliters) white blood cell counts were depleted of residual T lymphocytes and low-density cells (primarily macrophages) by consecutive steps of E rosetting, complement-mediated lysis of OKT3+ and OKT4+ cells, and Percoll density gradient centrifugation. No OKT3+ T cells were detectable in these cell populations before or after culture. When incubated for 3 days with phorbol ester plus recombinant human IL 2 (rIL 2), 12 to 57% of highly purified B cells from four of five tested patients expressed Tac antigen. Both phorbol ester and rIL 2 were required for maximal Tac antigen expression. Functional studies revealed that phorbol ester-activated (but not resting) CLL B cells responded to rIL 2 with [3H]thymidine incorporation and with enhanced secretion of IgM. Tac+ B cells were isolated in two cases on a fluorescence-activated cell sorter. In one patient, stimulation of Tac+ B cells with rIL 2 resulted in enhanced [3H]thymidine incorporation but no change in IgM secretion, as compared with Tac- B cells; in the second patient, stimulation of Tac+ B cells with rIL 2 did not result in [3H]thymidine uptake, but did result in significant IgM secretion. These findings indicate that certain leukemic B lymphocytes can be induced to express IL 2 receptors and respond to IL 2. The use of resting clonal B cell populations arrested at distinct stages of differentiation may help to better define the stage(s) at which IL 2 acts directly on B cells to induce proliferation and/or terminal differentiation.This publication has 17 references indexed in Scilit:
- Characterization of the human receptor for T-cell growth factor.Proceedings of the National Academy of Sciences, 1983
- Blockade of the interleukin-2 receptor by anti-Tac antibody: inhibition of human lymphocyte activation.The Journal of Immunology, 1983
- Density separation of chronic lymphocytic leukemia cells: Low-density non-T cells are efficient stimulator cells in allogeneic and autologous mixed leukocyte reactionClinical Immunology and Immunopathology, 1983
- B cell growth factor and T cell growth factor produced by mitogen-stimulated normal human peripheral blood T lymphocytes are distinct molecules.The Journal of Immunology, 1982
- Modulation of chronic lymphocytic leukemia cells by phorbol ester: increase in Ia expression, IgM secretion and MLR stimulatory capacity.The Journal of Immunology, 1982
- Modulation of T leukaemic cell phenotype with phorbol esterInternational Journal of Cancer, 1982
- HETEROGENEITY OF THE RESPONSE OF CHRONIC LYMPHOCYTIC-LEUKEMIA CELLS TO PHORBOL ESTER1982
- B cell helper factors. I. Requirement for both interleukin 2 and another 40,000 mol wt factor.The Journal of Experimental Medicine, 1981
- A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells.The Journal of Immunology, 1981
- T Cell Growth Factor: Parameters of Production and a Quantitative Microassay for ActivityThe Journal of Immunology, 1978